ClinVar Miner

Submissions for variant NM_000153.4(GALC):c.1887del (p.Trp629fs)

dbSNP: rs1884765073
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001212476 SCV001384059 pathogenic Galactosylceramide beta-galactosidase deficiency 2022-11-07 criteria provided, single submitter clinical testing ClinVar contains an entry for this variant (Variation ID: 942480). This premature translational stop signal has been observed in individual(s) with GALC-related conditions (Invitae). This variant disrupts a region of the GALC protein in which other variant(s) (p.Val681Met) have been determined to be pathogenic (PMID: 23462331, 31885218). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This sequence change creates a premature translational stop signal (p.Trp629Cysfs*6) in the GALC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 57 amino acid(s) of the GALC protein. This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.